An Overview Of A Study Of Bb2121 In Multiple Myeloma

An Overview of a Study of bb2121 in Multiple Myeloma

Targeted Oncology

Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma

Targeted Oncology

Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma

bb2121: bringing CAR T-cells into the multiple myeloma world

VJHemOnc – Video Journal of Hematology & HemOnc

ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results

International Myeloma Foundation

bb2121: a promising outlook for the future of multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

CAR T-Cells Multiple Myeloma: Adam Sperling, MD, PhD

Dana-Farber Cancer Institute

Jesus Berdeja | EHA 2018 | Summary of the CRB-401 phase I bb2121 CAR T-cell study

Multiple Myeloma Hub

Clinical Trials in Multiple Myeloma

International Myeloma Foundation

Results from CAR T-cell bb2121 first-in-human trial for R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Update on bb2121 for relapsed myeloma

Dr. Berdeja Discusses Study of bb2121 Anti-BCMA CAR-T Cell Therapy

CAR T-cells in Multiple Myeloma

Dana-Farber Cancer Institute

Dr. Raje Discusses the Tolerability of bb2121 in Myeloma

Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma

Clinical Trial: bb2121 CAR T Therapy, Larry Anderson, MD

HealthTree Foundation for Multiple Myeloma

Our Research Into Multiple Myeloma Treatment In 60 Seconds | Stand Up To Cancer

Stand Up To Cancer UK

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

International Myeloma Foundation

Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in RR Multiple Myeloma

International Myeloma Foundation